[Primary radiotherapy and short androgen deprivation therapy of 18 months may be sufficient in patients with localized prostate cancer with high-risk-factor compared to the standard of 28 to 36 months]
- PMID: 31073701
- DOI: 10.1007/s00066-019-01470-5
[Primary radiotherapy and short androgen deprivation therapy of 18 months may be sufficient in patients with localized prostate cancer with high-risk-factor compared to the standard of 28 to 36 months]
Comment on
-
Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial.Eur Urol. 2018 Oct;74(4):432-441. doi: 10.1016/j.eururo.2018.06.018. Epub 2018 Jul 3. Eur Urol. 2018. PMID: 29980331 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
